Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates

Group 1: Earnings Performance - Caribou Biosciences reported a quarterly loss of $0.39 per share, slightly better than the Zacks Consensus Estimate of a loss of$ 0.40, and consistent with the loss of $0.39 per share from the previous year, indicating an earnings surprise of 2.50% [1] - The company posted revenues of$ 2.08 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 18.23%, and down from $3.56 million in the same quarter last year [2] - Over the last four quarters, Caribou has surpassed consensus EPS estimates three times, but has only topped revenue estimates once [2] Group 2: Stock Performance and Outlook - Caribou Biosciences shares have declined approximately 27% since the beginning of the year, contrasting with the S&P 500's decline of 1.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$ 0.44 on revenues of $3.5 million, and for the current fiscal year, it is -$ 1.78 on revenues of $11.4 million [7] - The estimate revisions trend for Caribou is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Caribou belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]